
In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.
During a conversation on the Trump administration’s 2025 drug pricing policies, panelists discussed the implications of the Most Favored Nation policy, the broader context of drug pricing reforms, and efforts to address pharmacy benefit manager (PBM) reform through greater transparency.
Ryan Haumschild, PharmD, MBA, MS, CPEL, vice president of pharmacy at Emory Healthcare and Winship Cancer Institute, moderated the discussion on June 26 with:
The majority of the conversation focused on the Most Favored Nation executive order, which President Donald Trump issued on May 12. This order revisits one from his first presidency. Not only did the first iteration of this policy face legal challenges, but after Trump lost his re-election, the Biden administration rescinded the rule, which ended the model.
About a week after the executive order was signed, HHS announced it had already identified specific pricing targets for manufacturers, signaling a clear intent for immediate and aggressive action.
As for other pricing policies, O’Brien outlined the importance of addressing broader systemic issues in health care, while Oubre and Favaro discussed the challenges of biosimilar adoption and the need for targeted solutions to address payer issues.
Watch the full conversation above or jump ahead in the conversation using the time stamps below:
Dual-Eligible Beneficiaries’ Grocery Supplemental Benefit Use and Health Care Utilization
October 23rd 2025Medicare Advantage grocery supplemental benefit use is associated with increased outpatient care, suggesting that policy changes allowing for nonmedical supplemental benefits could improve beneficiaries’ health, especially for dual-eligible beneficiaries.
Read More
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD
October 20th 2025Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.
Read More
Dual-Eligible Beneficiaries’ Grocery Supplemental Benefit Use and Health Care Utilization
October 23rd 2025Medicare Advantage grocery supplemental benefit use is associated with increased outpatient care, suggesting that policy changes allowing for nonmedical supplemental benefits could improve beneficiaries’ health, especially for dual-eligible beneficiaries.
Read More
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD
October 20th 2025Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.
Read More
2 Commerce Drive
Cranbury, NJ 08512